MK-677 (Ibutamoren) Compassionate Use and Expanded Access: What Patients Need to Know in 2026

What Is MK-677 (Ibutamoren) and Why Do Patients Want Access?

Ibutamoren is a selective, non-peptide agonist of the ghrelin receptor (GHSR-1a). Oral dosing at 10 to 25 mg/day stimulates pulsatile growth hormone (GH) secretion and raises insulin-like growth factor 1 (IGF-1) concentrations without requiring injections. That profile attracts patients managing age-related GH decline, muscle wasting, and poor sleep quality.

The Clinical Evidence Base

The most frequently cited human trial is a 12-month, double-blind, placebo-controlled study (N=65, mean age 24.5 years) by Nass et al. Published in the Journal of Clinical Endocrinology and Metabolism. Participants receiving 25 mg/day showed statistically significant increases in IGF-1 and GH pulse amplitude versus placebo, alongside modest lean mass gains. [1]

A second Merck-sponsored trial (NCT00619151, N=536 hip-fracture patients, mean age 79) assessed 25 mg/day ibutamoren for 24 months. The trial was halted early after cardiac adverse events occurred at a higher rate in the treatment arm, an outcome the FDA noted when evaluating the compound's clinical risk profile. [2]

Why No FDA Approval Exists

Merck discontinued ibutamoren's clinical development program before filing a New Drug Application. No other sponsor has filed an NDA or BLA for ibutamoren in the United States. Without an approved application, routine prescription, pharmacy dispensing, and manufacturer-backed patient-access programs cannot legally exist. The FDA's drug database confirms no approved product under the INN "ibutamoren." [3]

What Compassionate Use and Expanded Access Actually Mean

These two terms are often used interchangeably online, but they describe distinct regulatory mechanisms under 21 CFR Part 312. Getting the distinction right matters before a patient or physician takes any action.

Compassionate Use (Emergency IND)

"Compassionate use" under FDA terminology refers to emergency Investigational New Drug (IND) applications for individual patients with serious or life-threatening conditions who have exhausted approved options. The FDA describes this pathway as: "an investigational drug... Available outside of a clinical trial to a patient with a serious or immediately life-threatening disease or condition." [4]

For ibutamoren, this pathway faces a concrete barrier: a licensed physician must be willing to serve as the IND sponsor, and the drug manufacturer must agree to provide the compound and data. With Merck no longer developing MK-677 and no current NDA sponsor on record, obtaining manufacturer cooperation is nearly impossible for most patients in 2026.

Expanded Access (Individual Patient IND)

Expanded access is the broader, non-emergency version of the same framework. A physician can apply to FDA for a single-patient IND using FDA Form 3926. The application requires an IRB review, institutional oversight in most cases, and documented evidence that potential benefit outweighs risk. [4]

The practical rate of success for unapproved growth hormone secretagogues through this pathway is extremely low. Patients with documented, severe GH deficiency are more likely to qualify for approved recombinant human GH products (somatropin) or, in some cases, tesamorelin (Egrifta), which does carry FDA approval for HIV-associated lipodystrophy. [3]

Current Legal Status of MK-677 in the United States (2026)

MK-677 occupies a gray zone in U.S. Law. It is not a scheduled controlled substance under the DEA's Controlled Substances Act. It is also not FDA-approved. This means:

• Manufacturers may sell ibutamoren as a "research chemical" or "laboratory reagent" for non-human, in-vitro research.
• Labeling it for human consumption or marketing it as a dietary supplement violates the Federal Food, Drug, and Cosmetic Act because ibutamoren is an article that has been authorized for clinical investigation. The FDA has specifically warned the supplement industry about GHRP compounds falling under this exclusion. [5]
• Physicians cannot write a legal prescription for ibutamoren in the standard pharmacy system because there is no approved drug product to prescribe.

The FDA's guidance on research chemicals states that a compound authorized for investigation under an IND cannot be marketed as a dietary supplement, regardless of its scheduling status. [5]

Who Might Qualify for a Legitimate IND Pathway?

Very few patients meet the bar for an individual patient IND for ibutamoren. The FDA expects applicants to demonstrate:

1. A serious or life-threatening condition (or a condition causing significant impairment) that cannot be addressed by approved therapies.
2. Documented failure of or contraindication to approved alternatives.
3. A physician sponsor who accepts full regulatory responsibility.

Conditions Where an IND Might Be Considered

Patients with documented, severe adult GH deficiency (defined by the Endocrine Society as a peak GH <3 mcg/L on stimulation testing, or <5 mcg/L using GHRH-arginine) who cannot tolerate injectable somatropin might theoretically explore an IND. The Endocrine Society's 2011 clinical practice guideline on adult GH deficiency outlines approved diagnostic thresholds and treatment standards. [6]

Patients with severe muscle-wasting conditions secondary to HIV, cancer cachexia, or short bowel syndrome should first exhaust approved options: somatropin (multiple brands), mecasermin (Increlex for IGF-1 deficiency), and tesamorelin (Egrifta). Bypassing approved agents to seek an experimental compound does not satisfy the FDA's "exhausted alternatives" requirement for expanded access. [3]

The Physician's Role Is Non-Negotiable

No IND can proceed without a physician sponsor. The FDA Form 3926 process for individual patient access requires the treating physician to certify the clinical rationale, agree to adverse event reporting, and obtain IRB concurrence (or document the reason a waiver applies). Patients cannot self-file an IND. [4]

How to Get MK-677 Cheaper: Legal and Practical Cost-Reduction Strategies

Since no prescription pathway exists, patients who are obtaining ibutamoren as a research chemical are doing so outside the traditional pharmacy system. That means standard prescription discount tools, GoodRx, manufacturer copay cards, patient assistance programs, do not apply. Below are the options that do have some practical relevance.

Understand the Real Cost Drivers

Research-chemical ibutamoren is sold in capsule or powder form by peptide and research-chemical vendors. Prices in early 2026 range from approximately USD 40 to USD 120 for a 30-day supply at 25 mg/day, depending on:

• Vendor reputation and third-party certificate of analysis (COA) availability.
• Capsule form versus raw powder (powder is generally 30 to 50% less expensive but requires accurate milligram-level measurement).
• Order quantity (bulk purchases of 90- or 180-day supplies frequently carry per-unit discounts of 15 to 25%).

Purchasing on the basis of price alone introduces serious safety concerns. A 2023 analysis of peptide and research-chemical products purchased online found that 44% of products tested had active ingredient concentrations outside ±10% of label claim, and several contained unidentified contaminants. [7] Low price frequently correlates with poor quality control.

Third-Party Tested Vendors

The most practical cost-reduction strategy is selecting a vendor that publishes up-to-date, batch-specific certificates of analysis from an accredited, independent laboratory, not in-house testing. Independent testing typically adds USD 5 to 15 per unit to vendor costs, which is reflected in price. Paying that premium is the only way to verify that the compound and dose are what the label states.

Bulk Ordering and Subscription Models

Several research-chemical vendors offer subscription discounts of 10 to 20% for recurring monthly orders. Combined with bulk quantity pricing, a patient purchasing a 90-day supply on subscription might reduce per-day cost from USD 2.50 to 4.00 to USD 1.50 to 2.50. These savings are real but do not change the legal or safety profile of the compound.

Telehealth Clinics and Compounding

Some telehealth clinics market MK-677 as part of "peptide therapy" or "longevity" protocols. These clinics typically operate through one of two models:

1. Physician-supervised monitoring with the patient self-sourcing ibutamoren from a research-chemical vendor.
2. Compounding pharmacies that prepare ibutamoren under a physician's order.

Model 2 exists in a particularly unclear regulatory space. The FDA has not designated ibutamoren as a bulk substance eligible for compounding under Section 503A or 503B of the FD&C Act. Compounding pharmacies that prepare ibutamoren may be doing so outside FDA-compliant pathways. Patients should verify the pharmacy's PCAB accreditation status and confirm their physician is aware of the regulatory uncertainty. [5]

Can I Use HSA or FSA Funds for MK-677?

No. Health Savings Account (HSA) and Flexible Spending Account (FSA) funds can only be used for "qualified medical expenses" as defined in IRS Publication 502. A qualified medical expense generally requires a valid prescription for an FDA-approved drug or a physician's documentation of medical necessity for a recognized treatment. [8]

Because ibutamoren has no FDA approval and cannot be legally prescribed through the standard pharmacy system, it does not meet the IRS definition. Using HSA or FSA funds to purchase ibutamoren would constitute a non-qualified distribution, subject to income tax on the amount withdrawn plus a 20% penalty for individuals under age 65. [8]

Some patients have asked whether a physician's letter documenting off-label use could qualify ibutamoren for HSA/FSA reimbursement. The IRS standard requires the drug itself to be a legal, prescribed medication, a letter of recommendation does not change the drug's regulatory status.

Safety Considerations That Affect Access Decisions

Any cost-reduction strategy that compromises product quality adds clinical risk. The safety signal from the Merck hip-fracture trial (increased cardiac events in elderly patients) is the most serious concern in the clinical record. [2] Additional documented adverse effects include:

Insulin Resistance and Glucose Elevation

In the 12-month Nass et al. Trial, fasting glucose increased by approximately 0.3 mmol/L and fasting insulin rose significantly in the ibutamoren arm compared to placebo. [1] Patients with pre-diabetes, metabolic syndrome, or a first-degree family history of type 2 diabetes carry elevated risk. The American Diabetes Association's Standards of Care recommend fasting plasma glucose monitoring for any intervention known to affect insulin sensitivity. [9]

Fluid Retention and Blood Pressure

GH-mediated sodium retention causes transient edema, particularly during the first 2 to 4 weeks of dosing. In patients with hypertension, heart failure, or renal impairment, this effect may be clinically significant.

IGF-1 Elevation and Cancer Risk Hypothesis

Sustained supraphysiologic IGF-1 levels are associated in epidemiological studies with increased risk of colorectal, prostate, and breast cancers. A large prospective analysis published in The Lancet Oncology (N=3,609) found a statistically significant association between IGF-1 in the top quartile and prostate cancer risk (OR 1.54, 95% CI 1.22 to 1.96). [10] This association does not prove causation from pharmacologic IGF-1 elevation, but it informs the risk-benefit discussion for long-term ibutamoren use.

What to Tell Your Physician

A straightforward conversation with your physician is the most productive access strategy. Bring the following:

• The Nass et al. JCEM paper [1] and the NCT00619151 trial record [2] so the discussion is grounded in trial data, not online forum claims.
• Your most recent IGF-1 and fasting glucose labs (if available).
• A description of what you are already taking and why you believe ibutamoren might add benefit.

Physicians who specialize in endocrinology, sports medicine, or age-management medicine are more likely to be familiar with the compound's trial history and can order baseline and monitoring labs (IGF-1, fasting glucose, HbA1c, blood pressure) even if they cannot write a standard prescription.

The Endocrine Society's clinical practice guideline on adult GH deficiency states: "Treatment with GH should be initiated at a low dose... And titrated based on clinical response, IGF-1 levels, and side effects, not on a fixed weight- or body surface area-based regimen." [6] That principle applies by analogy when monitoring any GH-axis intervention.